Publications by authors named "C N Makhale"
Article Synopsis
- Home time, or the duration patients with cardiovascular disease spend alive outside of healthcare institutions, is an essential aspect of recovery, particularly for heart failure (HF) patients, yet insufficiently studied in India where HF rates are increasing.
- Current literature falls short in identifying hospital-level trends and predictors of home time, which complicates the development of personalized care strategies to enhance health outcomes, functional status, and reduce hospitalization risks.
- While guideline-directed medical therapy, especially sacubitril/valsartan (an angiotensin receptor neprilysin inhibitor), is well-supported for improving life quality and reducing HF-related hospitalizations, its use remains low, indicating a critical need for better integration into clinical practice to improve patient recovery and home time post
Purpose: Compared with healthy individuals, patients with peripheral artery disease (PAD) generally have a very high risk of subclinical Coronary artery disease (CAD) and cardiovascular events. To determine the correlation between CAD in PAD patients, thereby promoting the lifetime of PAD patients and reducing the serious impacts of CAD.
Methods: This clinical-based cross-sectional study comprised 100 consecutive patients in India from 2014 to 2016.
Ticagrelor is a potent, oral P2Y12 inhibitor used as a part of dual antiplatelet therapy (DAPT) in acute coronary syndromes (ACS). New evidence has emerged for its use in ACS, which may be crucial for the Indian context. This brought together nearly 150 experts in ACS management across the country who reviewed the current evidence and discussed the same through a series of 10 meetings on an online platform.
View Article and Find Full Text PDFObjectives: To evaluate the safety and performance of the Hydra transcatheter aortic valve (THV) in the treatment of symptomatic severe aortic stenosis in patients at high or extreme surgical risk.
Background: The Hydra THV (Vascular Innovations Co. Ltd.